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1 INTRODUCTION 
 
The fields of chemistry and biology are 
marvellously intertwined. The fact that one can 
describe the basis of biological phenomena, both 
those that are complex (such as inflammation, or 
the onset of cancer) and ‘commonplace’1 (such as 
the digestive process, or the transport of oxygen by 
the blood) in terms of the interactions of molecules, 
has always fascinated me. Proteins, and more 
particularly enzymes (i.e. proteins that catalyse 
chemical reactions), have held a particular attraction: 
since they are made up of 20 simple building blocks 
(called amino acids), which can be arranged in any 
order and any combination, they are exceedingly 
diverse in terms of their structures, the type of 
reactions they catalyse and the specific compounds 
that they act upon. They have to be, considering the 
vast range of biological processes that directly 
depend on their activity. Yet all of these aspects can 
often be explained in simple molecular terms, using 
chemical language that refer to the making and 
breaking of bonds, or the interactions between 
specific groups in the enzymes and those in its 
substrate, or to the importance of acid/base 
chemistry, for example. Moreover, understanding an 
enzyme on this level often makes it possible for its 
activity to be manipulated in some way. For 
example, its substrate specificity or the way in which 
it is regulated can be changed by exchanging one or 
more of its amino acid building blocks for another. 
Similarly, a compound can be designed to have a 
structure that mimics the specific interactions that 
the substrate has with the enzyme, without acting as 
such a substrate itself. Such compounds will act as 
inhibitors of that enzyme’s activity—they will occupy 
the space that the enzyme normally uses for 
catalysis—and can be used in a variety of 
therapeutic applications: antibiotics, antipsychotics, 
anti-inflammatory agents and much more. Such 
                                                     
1 Some would argue that it is impossible to make such a 
distinction. Once even the ‘commonplace’ phenomena 
are studied and better understood, more often than 
not they turn out to be exceedingly complex! 
tinkering on a molecular level—molecular 
engineering, in a manner of speaking—is only really 
made possible by a deep and fundamental 
understanding of the chemical principles that 
underlie bonding and reactivity.  
Scientists that actively work on such research 
questions come from diverse backgrounds: some 
are chemists (itself a very diverse field), others are 
biochemists, or medical scientists—the list is quite 
long. However, within the last 15 years or so a 
group of these scientists felt the need to describe 
the endeavour of addressing biological problems by 
using chemical tools and applying chemical thinking 
more directly. Thus the field of chemical biology 
was coined—although, to be honest, similar kinds of 
studies were previously performed under names 
such as ‘bioorganic chemistry’, ‘bioinorganic 
chemistry’ or ‘biological chemistry’.2 Nonetheless, 
scientists are not immune to the concept of fashion, 
and several well-known departments of ‘chemistry’ 
(such as the one at Harvard University) were 
renamed as departments of ‘chemistry and chemical 
biology’ during this time. This period exactly 
coincided with my undergraduate studies, and by 
the time that I was completing my BSc(Hons) 
degree (in chemistry) at the University of Pretoria, 
my awareness of this burgeoning field had grown 
significantly—as did my excitement to conduct my 
postgraduate studies doing such work. 
Unfortunately, very few academic researchers in 
South Africa were working at the chemistry/biology 
interface at the time,3 which eventually led me to 
pursue my studies abroad. I was accepted into the 
                                                     
2 Those with lexicographic inclinations might ask how 
‘chemical biology’ differs from ‘biological chemistry’. The 
simplest answer is that on the deepest level, they really 
don’t. But we can all cite examples of how the need to 
excite prospective funders/clients/voters gave rise to a 
new name for what essentially remained the same 
animal. In marketing this is referred to as ‘rebranding’, 
and apparently scientists are also pretty good at it. 
3 It was only after I joined Stellenbosch University that I 
discovered that several of the members of the 
Department of Biochemistry (now my colleagues) had 
been doing exactly this for many years! 
4 
graduate programme in the Department of 
Chemistry and Chemical Biology (they too 
succumbed to the name-changing pressures) at 
Cornell University in the USA, and there started my 
own career as a ‘chemical biologist’ in the group of 
Tadhg Begley.4 Tadhg, who himself received 
postdoctoral training from both a synthetic organic 
chemist5 and an enzymologist, was one of the 
central players in defining the field of chemical 
biology. In his words: “Chemical Biology can be 
viewed as subsuming important aspects of the 
traditional disciplines of bioorganic chemistry, 
bioinorganic chemistry, medicinal chemistry, 
biophysical chemistry and biochemistry, with a 
special emphasis on the rigorous application of the 
principles, tools and language of chemistry to 
important topics in biology”.6 
Since my return to South Africa, and especially 
after having started my own research group, I have 
been mindful of also emphasising such a “rigorous 
application” of chemistry in our studies. This article 
will describe some of the highlights of these studies, 
which have as their focus the biology of coenzyme 
A biosynthesis, with the goal of applying the new 
knowledge we gain to address various challenges in 
human health. The next section provides some 
context for this area of research. 
                                                     
4 Tadhg is a native of Ireland who moved to the United 
States to pursue his PhD studies and eventually also 
started his academic career there. His name is Irish 
Gaelic, and is pronounced “Tai-gue”. When I once 
commented to him how hard it can be to write in 
English when it was one’s second language, he 
remarked that he fully understood: it was his second 
language as well. His schooling was completely in 
Gaelic. 
5 The world is indeed very small: the synthetic organic 
chemist in question was Wolfgang Oppolzer at the 
University of Geneva in Switzerland, the same person in 
whose group my father—a synthetic organic chemist by 
training—worked as a postdoctoral fellow. That was in 
1981; Tadhg joined Oppolzer’s group just a few years 
later (in 1983), by which time our family had already 
returned to South Africa. I very nearly first met him 
when I was pre-schooler! 
6 Quote cited by Prof Patrick Guiry, Director of the 
Centre for Synthesis & Chemical Biology, University 
College Dublin on 16 June 2010, as part of the 
introductory address on the occasion of the conferring 
of an honorary Doctor of Science degree on Tadhg 
Begley from the National University of Ireland. 
(http://www.ucd.ie/president/universityawards/honrorar
ydegree/09-10/tagdh-begley/; accessed 2014/02/03) 
2 OF VITAMINS AND COFACTORS 
 
Vitamins receive a lot of attention these days. 
We are told to eat certain foods because they are 
rich in certain vitamins, and to take multi-vitamin 
supplements on a daily basis to make up for the 
shortfall in our diet. Some vitamins are also hailed as 
‘anti-oxidants’, or are supposed to have other 
special medical benefits. But what are vitamins 
exactly, and why do we need them? 
Vitamins are organic7 chemical compounds that 
are vital for the survival of a particular organism, but 
which the organism cannot make itself. They are 
therefore essential nutrients, and consequently must 
form part of a balanced diet—although usually only 
in limited amounts.8 Lack of any particular vitamin 
results in a disease specifically associated with such a 
deficiency, and can result in death in some cases. 
Importantly, the requirement for vitamins is different 
for different organisms; plants, for example, are able 
to synthesise most of the vitamins, and are 
therefore a good dietary source of them. Currently 
13 vitamins are recognised; their names and 
associated deficiency diseases are listed in Table 1. 
Each of the vitamins has a very specific biological 
function. Vitamin C, for example, plays a key role in 
reversing damage in one of the enzymes involved in 
the formation of collagen, the protein that provides 
structure to connective tissues such as tendons, 
ligaments and skin. In fact, most of the vitamins 
serve as precursors to so-called ‘cofactors’, which 
are helper molecules that are either attached to or 
closely associated with some enzymes to allow 
them to perform chemical reactions they would 
otherwise be incapable of doing. As such, they 
expand the chemical versatility of these enzymes, 
since their constituent 20 amino acid building blocks 
are actually not very diverse from a chemical and 
structural point of view.  
                                                     
7 While the term ‘organic’ is currently used to refer to 
foodstuffs that are grown and raised without the 
application or addition of man-made chemicals, in a 
chemical sense it refers to any compound that consists 
of at least the elements carbon (C) and hydrogen (H), 
and any combination of these with oxygen (O), 
nitrogen (N), phosphorus (P) and sulphur (S). 
8 The fact that vitamins only need to be taken in small 
quantities is often overlooked. Some people have the 
point of view that if a little bit of something is good, a 
lot of it must be better. However, consuming an excess 
of certain vitamins could cause a variety of adverse 
effects. 
5 
Table 1. The 13 vitamins, their various chemical forms, deficiency diseases and associated cofactors (Johnson, 2013). 
Vitamin Chemical form(s) Deficiency disease Associated cofactor(s) 
Vitamin A Retinol, retinal, other 
carotenoids (e.g.  -carotene) 
Night-blindness, hyperkeratosis, 
and keratomalacia 
 
Vitamin B1 Thiamine 
Beriberi, Wernicke-Korsakoff 
syndrome Thiamine pyrophosphate (TPP) 
Vitamin B2 Riboflavin Ariboflavinosis 
Flavin mononucleotide (FMN),
flavin adenine dinucleotide (FAD) 
Vitamin B3 Niacin, niacinamide Pellagra 
Nicotinamide adenine dinucleotide
(NAD+) and its phosphate (NADP+) 
Vitamin B5 Pantothenic acid 
Deficiency is very rare; 
‘pins and needles’ Coenzyme A (CoA) 
Vitamin B6 
Pyridoxine, pyridoxamine, 
pyridoxal 
Anaemia, peripheral neuropathy Pyridoxal phosphate (PLP) 
Vitamin B7 Biotin Dermatitis, enteritis Biotin 
Vitamin B9 Folic acid, folinic acid 
Birth defects when deficient in 
pregnancy; megaloblastic anaemia 
Tetrahydrofolic acid (THF) 
Vitamin B12 
Cyano-, hydroxyl- and 
methylcobalamin Megaloblastic anaemia Cobalamin, methylcobalamin 
Vitamin C Ascorbic acid Scurvy Ascorbic acid 
Vitamin D Cholecalciferol, ergocalciferol Rickets and osteomalacia  
Vitamin E Tocopherols, tocotrienols 
Deficiency is very rare; mild 
haemolytic anaemia in newborns  
Vitamin K 
Phylloquinone, 
menaquinones Bleeding diathesis Menaquinone 
 
One of the B vitamins, called vitamin B5 or 
pantothenic acid,9 is the precursor for the cofactor 
coenzyme A (CoA), which acts as the main acyl 
group carrier in biological systems. Acyl groups are 
the derivatised forms of organic acids, which include 
acetic acid (the principle component of vinegar, with 
two carbon atoms) and the longer fatty acids 
palmitic (16 carbons) and stearic acid (18 carbons). 
To be carried by CoA, these acids are attached to 
its thiol (–SH) group, as shown for palmitic acid in 
Figure 1.10 This attachment increases the solubility of 
                                                     
9 The name ‘pantothenic acid’ is derived from the Greek 
word for ‘from everywhere’, since it is found in nearly 
all foods. Consequently, a clinical deficiency in the 
vitamin has not been described. Its alcohol derivative 
pantothenol (from reduction of the acid) is widely used 
in hair and skin care products, where it is referred to as 
“pro-vitamin B5”—most likely to capitalise on the 
positive emotional value of vitamins in general. 
However, in these products its function is mainly to act 
as moisturiser and to give hair its shiny appearance. 
10 The ‘stick’ structures used in this figure is one of the 
ways in which the structures of organic molecules are 
often represented. It is a convention, just as writing 
from left to right is a convention, and for the uninitiated 
may look like total gibberish. For such people my advice 
the acids in aqueous solutions and also makes it 
possible for them to be spatially manipulated; the 
CoA becomes a ‘handle’ that allows for enzymes to 
attach to and perform reactions on them. 
Additionally, the coupling of these acids to the thiol 
of CoA changes their chemical characteristics, which 
makes it possible for them to undergo chemical 
reactions that would otherwise not have occurred. 
For example, this allows for the two-carbon acetate 
units to be joined into longer fatty acids. It also 
makes the reverse reaction, i.e. the breakdown of 
fatty acids, possible. As such, CoA is usually 
associated with the biochemistry and metabolism of 
fatty acids, while acetyl-CoA is additionally also 
involved in the central metabolic processes that 
generate energy from various carbon sources. 
Several regulatory processes also depend on the 
acetyl group being transferred to and removed from 
proteins and other small molecules. 
                                                                                   
is usually to treat such schemes as spot-the-difference 
games: compare the structures on either side of the 
arrow, and try to identify the differences between 
them. The crux of what is being shown—here, the 
attachment of the fatty acid to the thiol of CoA—
usually becomes clear in this way. 
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Figure 1. CoA as acyl group carrier: the fatty acid 
palmitic acid, which is poorly soluble in water and difficult 
to manipulate in enzyme reactions, is converted to 
palmitoyl-CoA by attachment to the thiol (–SH) group of 
CoA. In this way its solubility is improved, and the CoA 
component becomes a ‘handle’ that enzymes can use to 
hold on to the molecule while performing reactions on it. 
 
Taken together, CoA is an extremely versatile 
cofactor which is involved in several central 
metabolic processes. By my own calculation at least 
9% of all known enzyme activities make use of it 
directly, or rely on one of its derivatives. 
Consequently CoA draws much attention from 
researchers in diverse fields in biology. My group’s 
main interest in CoA has been the biosynthetic 
process by which its vitamin precursor (pantothenic 
acid) is converted to CoA. A detailed description of 
this process follows in the next section. 
 
 
3 ONE PATHWAY, MANY PATHS 
 
3.1 The universal CoA biosynthetic pathway 
Pantothenic acid is converted to CoA in five 
enzyme-catalysed steps, which are summarised 
schematically in Figure 2. For the rest of this article 
the enzymes will only be referred to by their 
abbreviated names—PanK, PPCS, PPCDC, PPAT 
and DPCK—and only the details that are relevant 
to the highlights presented here will be provided.  
For more detailed information on these enzymes 
and their characteristics interested readers are 
referred to a recent book chapter I authored on 
CoA biosynthesis and enzymology (Strauss, 2010). 
 
Figure 2. Schematic representation of the biosynthesis of 
CoA from pantothenic acid in five enzyme-catalysed 
steps (indicated by the black lines on the curved arrow; 
the abbreviation for each enzyme is given). The grey lines 
point to the biosynthetic intermediates. The portion of 
CoA that derives from pantothenic acid is circled in grey 
in its structure (Spry et al., 2010). 
 
To the best of our current knowledge, the CoA 
biosynthetic pathway is universal, meaning that all 
organisms convert pantothenic acid into CoA using 
these same five steps, with one small exception 
being found in the pathway active in the Archaea 
(Yokooji et al., 2009; Tomita et al., 2012; Katoh et 
al., 2013).11 Additionally, all organisms must 
synthesise CoA themselves, starting from 
pantothenic acid.12 In combination, these facts have 
several important implications. First, it means that 
                                                     
11 The Archaea are single-celled microorganisms 
(microbes) that are generally associated with extreme 
environments. They are also considered to be some of 
the oldest lineages on earth. In their CoA biosynthesis 
pathways, the first step of the universal CoA pathway 
does not exist. Instead, the phosphorylation occurs as 
part of the synthesis of pantothenic acid (the Archaea 
can synthesise the vitamin themselves). 
12 The mycoplasmas, primitive pathogenic bacteria that 
depend on their hosts for survival, are perhaps the only 
exception to this rule. Based on the currently available 
information these organisms prepare CoA from dPCoA 
(the penultimate biosynthetic intermediate), which 
would suggest that they must scavenge it from their 
hosts (Strauss, 2010). However, this must still be 
demonstrated experimentally. 
7 
studies of the pathway in simple organisms (such as 
the model bacterium, Escherichia coli) can be used 
to further our understanding of CoA biosynthesis in 
all organisms, including complex ones such as 
humans. On the other hand, differences that are 
discovered between two organisms can potentially 
be exploited for intervention of some kind. For 
example, differences between the human CoA 
biosynthetic pathway and the one in a pathogenic13 
bacterium that causes fatal infections in humans may 
offer opportunities for the discovery of new 
antibiotics (compounds that selectively kill the 
pathogen). Additionally, a better understanding of 
CoA biosynthesis, as well as its breakdown and 
utilisation, could potentially help us better manage a 
variety of disease states, including ones that have 
specifically been linked to mutations (genetic 
variations) in PanK, the first pathway enzyme.14 It is 
with respect to all these facets of CoA biosynthesis 
that my group’s research has been making a 
contribution. 
 
3.2 Discovery of the CoA biosynthetic enzymes 
Considering the central role of CoA in 
metabolism, and the relatively simple, linear pathway 
for its synthesis from pantothenic acid, it might be 
surprising for some to learn that when I started my 
PhD studies in 1998, only one of the five enzymes 
in the pathway (PanK) had been identified and fully 
characterised.15 However, within the next two years 
both the PPAT and DPCK enzymes from E. coli had 
been described. The two remaining enzymes—
PPCS and PPCDC—continued being elusive, and it 
was the first aim of my PhD research to purify and 
characterise the latter of these.  
Initially I went about doing this based on the little 
information that was available on the enzyme at the 
time—information that later turned out to be 
mostly wrong. By the time we had realised this, and 
changed our tactics, another research group had 
                                                     
13 In its broadest sense, a ‘pathogen’ is anything that can 
cause disease. The name (from the Greek) literally 
means ‘producer of suffering’. 
14 Pantothenate kinase-associated neurodegeneration 
(PKAN) is a rare, progressive degenerative brain 
disease that often causes death in early adulthood. It is 
estimated to affect 1 to 3 individuals in a million. 
15 The pathway, i.e. the actual transformations and 
biosynthetic intermediates, was discovered long before 
that, but only the PanK enzyme had been isolated and 
characterised, and the gene that encodes it in E. coli 
identified. 
already identified the PPCDC enzyme in E. coli using 
a completely different approach. Consequently, they 
published their findings within weeks of our own 
discovery of the enzyme, which made it a rather 
empty achievement. However, what seemed like a 
very grey cloud turned out to have a silver lining: by 
chance (and also by using some critical reasoning!) 
we uncovered that the PPCDC enzyme also had 
PPCS activity. This meant that in E. coli a single 
protein carried both the PPCS and PPCDC 
functions, which is a relatively uncommon 
occurrence in biosynthetic pathways. Even now, the 
functional relevance of this fusion is also not entirely 
clear. Nonetheless, this surprising finding allowed us 
to publish a report of the discovery and 
characterisation of the last remaining unidentified 
activity in the pathway in 2001 (Strauss et al., 2001). 
With that, the chapter on the discovery of CoA 
biosynthetic enzymes seemed to have been 
concluded. 
 
3.3 Variations in the CoA biosynthetic pathway 
With the advent of large scale genome 
sequencing,16 a vast amount of bioinformatic data17 
became available. Since CoA biosynthesis is such a 
conserved process (all organisms perform it in the 
same way), the general expectation was that the 
CoA biosynthetic enzymes should also not show 
much variation between organisms. This idea was 
tested by using the sequences of the five CoA 
biosynthetic enzymes in E. coli (and those 
subsequently discovered in other organisms) to 
search for genes in organisms with sequenced 
genomes that would encode similar proteins. In this 
way, a ‘map’ of the CoA biosynthetic enzymes in all 
these organisms could be drawn.  
                                                     
16 An organism’s genome is all of its hereditary 
information, which is usually contained in sequences of 
DNA. Within these sequences are the genes that code 
for the proteins that are active in that organism; each 
gene (usually) codes for a specific protein. Genome 
sequencing refers to the activity of determining these 
sequences, which is done using a variety of technologies 
and instruments. The speed and accuracy with which it 
is achieved have improved exponentially during the last 
decade. 
17 Bioinformatics refers to the study of the data that is 
obtained from genome sequencing, as well as the data 
that can be obtained from it either by inference (such 
as the identification of genes within the sequences, and 
the proteins that they code for) or by comparison, for 
example between organisms. 
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Figure 3. ‘Map’ of the variations in the CoA biosynthetic pathway in a range of organisms that exemplify the basic form of 
the pathway (with its subvariants) and several variants of it (Strauss, 2010). 
 
Figure 3 shows a recent version of this map, and 
demonstrates that the situation is not entirely as 
simple as originally thought, with a basic form of the 
pathway (with some subvariations) and at least four 
variants of it. These distinctions are based on several 
factors, and also take into account whether the 
organism is able to synthesise its own pantothenic 
acid, or can obtain it from its environment by 
transport it into the cell. Focusing on the CoA 
biosynthetic enzymes themselves, the following 
differences are the most obvious ones: at least three 
different types of PanK enzymes exist, and two 
forms of PPAT. Additionally, as explained above, the 
PPCS and PPCDC activities are found on a single 
bifunctional protein (called CoaBC) in all bacteria 
(the Streptococci and Enterococci being an 
exception). However, in animals and plants these 
are separate enzymes. The situation is reversed for 
PPAT and DPCK: they are separate enzymes in 
most bacteria, but are found on a bifunctional 
enzyme in animals. Additionally, some organisms 
apparently do not have complete CoA pathways: 
the mycoplasmas only have a DPCK, suggesting that 
they must obtain dPCoA from their hosts. 
Treponema pallidum, the causative agent of syphilis, 
is missing both PPCS and PPCDC activities, meaning 
it does not have a functional CoA biosynthesis—or 
it manages to circumvent these enzymes in a 
manner that we do not yet understand.  
Clearly, the diversity in the pathway exceeded all 
our expectations. My research group was involved 
in uncovering two of the more surprising variations: 
the discovery of a ‘missing’ PanK, and unravelling the 
reasons for the ‘inactive’ PPCDC in baker’s yeast. 
    
 
4 PANKIII: THE ‘MISSING’ ENZYME—
THAT WASN’T 
 
The map of CoA biosynthesis shown in Figure 3 
is a recent one, and indicates that the first enzyme 
in the pathway in the bacterium Pseudomonas 
aeruginosa (an opportunistic pathogen that cause 
respiratory infections) is a type III PanK. However, 
prior to 2005, only two types of PanK were known: 
a type I, which was first described in E. coli and 
seemed to predominate in bacteria, and a type II, 
which was found in higher organisms such as 
animals and plants (strictly speaking, in all 
eukaryotes18). Curiously, at this time no PanK could 
be identified in the genomes of a range of mainly 
pathogenic bacteria, among them the causative 
agents of stomach ulcers (Helicobacter pylori), 
whooping cough (Bordetella pertussis), meningitis 
(Neisseria meningitis), antibiotic-associated diarrhoea 
(Clostridium difficile) and hospital-associated 
                                                     
18 Eukaryotes are organisms that have cells with a nucleus 
(which contains the genetic material), and includes 
animals and plants, but also a range of micro-organisms: 
yeasts, and several different pathogenic parasites 
(including the one causing malaria), for example. 
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infections (Acinetobacter baumannii). This meant that 
in these organisms, which had all the other pathway 
enzymes, the PanK activity was ‘missing’ (Gerdes et 
al., 2006). 
A patent that appeared in 2002 seemed to hold 
the key to the mystery (Yocum & Patterson, 2002). 
As part of this patent’s stated claims, it was shown 
that it is possible to remove the gene encoding the 
type I PanK in the model bacterium Bacillus subtilis 
without having a fatal effect, suggesting that an 
enzyme encoded by another gene also had PanK 
activity. This was mapped to a gene dubbed ‘coaX’, 
with the ‘X’ used to denote that the corresponding 
enzyme’s normal function was unknown at that 
stage. I came across this finding while doing 
literature searches as part of the write-up of my 
PhD thesis, and decided to investigate these results 
in more depth when I launched my own 
independent career.  
The study and characterisation of the ‘CoaX’ 
enzymes therefore became the subject of the 
research project of my technical assistant and first 
MSc student (Leisl Brand). Together we discovered 
that the B. subtilis enzyme discovered in the patent 
was in fact the PanK that was ‘missing’ from the 
pathogenic bacteria. Even more importantly, the 
‘CoaX’ PanK was apparently much more widely 
distributed in bacteria than the supposedly 
predominant type I PanKs. Additionally, we also 
showed that the enzyme differed from the two 
known PanKs in almost every respect: their 
sequences, their kinetics, their phosphate donor 
specificity, and their sensitivity to known inhibitors. 
We published the first description of these type III 
PanKs (as we later dubbed this newly discovered 
form of the enzyme) in 2005 (Brand & Strauss, 
2005); in collaboration with Hong Zhang at UT 
Southwestern Medical Centre in the USA we also 
determined the first structure of a type III PanK, and 
published this in the following year (Yang et al., 
2006). This structure showed that while the type III 
PanKs belonged to the same fold as the type II 
enzymes, and that both types shared similar 
domains, the manner in which the dimer is formed 
in each case and their respective active site 
architectures are very different (Figure 4).  
In combination, these studies made a seminal 
contribution to our knowledge of CoA biosynthesis 
in bacteria, and established my group as one of the 
leading role players in the field internationally. My 
group is currently continuing our work on type III 
PanKs, with a specific focus on them as potential 
targets for antibiotic development. 
 
Figure 4. Structures of representative examples of the 
three bacterial PanK types: a type I PanK structure from 
E. coli (PDB ID: 1SQ5), the structure of a type II PanK 
from Staphylococcus aureus (PDB ID: 2 EWS), and the 
type III PanK from Thermatoga maritima (PDB ID: 3BEX). 
The differences between the types should be evident by 
comparing their respective ribbon structures. Note the 
similar domains in type II and III PanKs, combined with a 
very different interaction at the dimer interface. 
 
 
5 PPCDC IN YEAST: ACTIVITY IN 
THE MOONLIGHT 
 
In 2004 I was approached by a researcher in Spain, 
Prof Joaquín Ariño, with an interesting problem: 
they had isolated the protein from baker’s yeast 
(Saccharomyces cerevisiae) that was proposed to 
have PPCDC activity (based on homology, i.e. by 
comparing its sequence to that of known PPCDCs), 
but had failed to find any evidence for such an 
activity. Could we help? Thus began a long and 
fruitful collaboration that continues to this day, and 
which resulted in some surprising and extraordinary 
findings. But first, some background is required. 
 
5.1 The curious mechanism of PPCDCs 
PPCDC catalyses the decarboxylation of its 
substrate, that is, it removes a molecule of CO2 
from its substrate (see Figure 5). When we first set   
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Figure 5. PPCDC-catalysed reaction (in grey box) with 
the carboxyl group of PPC that is removed circled. On 
the right is the two-step mechanism, showing that the 
substrate is first oxidised prior to decarboxylation, and 
then reduced again. These two steps depend on two 
specific amino acid residues, a histidine (His) and cysteine 
(Cys) respectively. 
 
out to isolate the PPCDC enzyme as described 
earlier, we already knew that the enzyme must have 
an interesting mechanism from a chemical point of 
view. When the bond between the COOH group 
and the rest of the molecule is broken, negative 
charge builds up on the carbon backbone. 
However, carbon does not have the ability to deal 
well with such negative charges under normal 
circumstances, and the charge must therefore be 
stabilised in some manner. We envisaged several 
ways in which the enzyme could achieve this. In the 
end, reality turned out to be much more elegant 
than any of our proposals: the enzyme changes the 
substrate’s thiol (–SH) group into one that can 
facilitate the decarboxylation by an oxidation 
reaction (as shown in Figure 5); once the reaction is 
complete, a reduction reaction ensures that the 
thiol is formed again. Strictly speaking the enzyme 
temporarily installs a new functional group to do the 
difficult bond cleavage, and then removes it again. 
An important additional feature of this 
mechanism is that the oxidation and reduction 
reactions that make the decarboxylation possible 
each depend on a specific amino acid in the 
enzyme’s active site (i.e. the space in which the 
reaction takes place). The oxidation relies on a 
conserved (i.e. all PPCDC enzymes have it) histidine 
(His) residue, while the reduction depends on a 
conserved cysteine (Cys). Readers who are 
interested in the details of this mechanism and how 
it was elucidated are referred to the respective 
publications that detail these discoveries (Strauss & 
Begley, 2001; Strauss et al., 2004). 
5.2 Baker’s yeast’s remarkable PPCDC 
As remarked above, Joaquín Ariño’s group had 
already shown that Hal3, the yeast protein which is 
the closest homologue to E. coli’s PPCDC and the 
PPCDC from the plant Arabidopsis thaliana (in 
essence a weed, but widely used in laboratories as a 
model in the studies of plant genetics), did not 
exhibit any evidence of having PPCDC activity. 
However, they had identified an important deviation 
in Hal3 which could be the reason for this lack of 
activity: it did not have the conserved Cys residue 
necessary for the second part of the PPCDC 
reaction. Interestingly, they found that yeast had two 
other proteins that were closely related to Hal3 and 
which could be considered as potential PPCDC 
candidates. However, these proteins also did not 
have all the required active site residues: the one 
(Vhs3) had the His, but also lacked the Cys, while in 
the other (Cab3) the His was missing, but the Cys 
was present. This meant that not one of the 
PPCDC candidates in yeast would be able to show 
PPCDC activity on their own, and experiments 
indicated that this was indeed the case.  
The only known structure of a PPCDC 
enzyme—the one from A. thaliana, called 
AtHal3a—suggested a potential solution to the 
problem. The functional protein is a homotrimer, 
meaning that three identical versions of the same 
protein come together to form the enzyme. 
Additionally, an active site is found at the interface 
between each of the adjacent proteins, i.e. three 
active sites in total. Lastly, the two catalytically 
essential residues are found on opposite sides of the 
active site, meaning that the His and Cys that are 
involved in catalysis in a particular active site are 
found on different proteins. A schematic 
representation of the A. thaliana PPCDC AtHal3a is 
shown in Figure 6A. Based on this model, we 
envisaged that an active PPCDC would form in 
yeast if either Hal3 or Vhs3 (or both) that could 
provide the required His, would join with one Cab3 
that has the required Cys in a heterotrimeric 
protein (i.e. three different proteins in the same 
complex). A model of such a structure is shown in 
Figure 6B, which shows that, unlike AtHal3a with its 
three active sites, only one functional active site 
would form in such a case. Based on this model our 
two groups devised and executed several 
biochemical and genetic experiments to establish 
whether it was an accurate representation of the 
yeast PPCDC. We were very pleased when these 
experiments all supported our model! 
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Figure 6. Schematic representations of the homotrimeric 
PPCDC enzyme AtHal3a from the plant A. thaliana, 
which has three functional active sites formed at the 
three interfaces between the proteins (Panel A), and the 
corresponding heterotrimeric enzyme from the yeast S. 
cerevisiae, which has only one functional active site (Panel 
B) (Ruiz et al., 2009).  
 
The last part of the story is perhaps the most 
curious: Hal3, the first PPCDC candidate to be 
identified, in fact already had a known and 
established function. It acted as an inhibitor of 
another enzyme (the phosphatase Ppz1) and in this 
way played a key role in regulating yeast’s cell cycle 
and its ability to respond to the stress of growing in 
the presence of high salt concentrations. This meant 
that Hal3 had two completely unrelated functions: 
the first as a component of the active PPCDC, and 
the second as a regulatory protein. This 
characteristic qualified Hal3 as a so-called 
‘moonlighting’ protein, i.e. a protein that has one 
function, but then ‘moonlights’ in also performing 
another. Several such proteins have been identified 
to date, but we do not yet fully understand the 
functional relevance of ‘moonlighting’ in cellular 
physiology.  
We published this remarkable story in the 
journal Nature Chemical Biology (Ruiz et al., 2009); it 
was also accompanied by a ‘News and Views’ article 
to highlight the significance of our findings 
(Osterman, 2009). Subsequent to this study, 
Joaquín’s and my groups have continued to 
collaborate and have published two more articles 
that describe further details of this and related 
systems (Abrie et al., 2012; Molero et al., 2013); a 
third—on whether Hal3 could dissociate from one 
protein complex to join another—is currently being 
finalised. It has been (and continues to be!) a 
fascinating journey working with his group in 
unravelling the finer details of CoA biosynthesis in 
various yeasts, all while trying to grasp the 
significance of the system for CoA biosynthesis in 
higher organisms in general. 
6 REVERSING THE BENEFIT: COA 
BIOSYNTHESIS AS A DRUG 
TARGET 
 
Perhaps the most interesting prospect for 
research focused on CoA biosynthesis is the 
potential for the design and discovery of new 
antimicrobials,19 i.e. compounds that could be used 
in the treatment of infectious diseases. Two 
examples of our work in this regard are highlighted 
in the following sections. 
 
6.1 Pantothenamides as antivitamins 
The concept of using ‘antivitamins’ (i.e. 
compounds that inhibit metabolic processes that 
depend on a specific vitamin) as antimicrobials is not 
a new one. The sulphonamides or ‘sulpha drugs’, the 
very first antibiotics that were discovered in the 
1930s, were later found to impede the biosynthesis 
of folic acid (vitamin B9, see Table 1). One of these 
sulpha drugs—sulfamethoxazole—is still widely used 
today. This discovery led to a rush of studies in the 
1940s to discover compounds that similarly acted as 
antivitamins of the other vitamins, but none were as 
successful as the sulphonamides, and with a few 
exceptions research in this field has been mostly 
abandoned (Shapiro, 2013). However, one study 
published more than 40 years ago demonstrated 
that pantothenamides—analogues of pantothenic 
acid (vitamin B5) in which its carboxyl is converted 
to an amide—show inhibition of the growth of 
several kinds of bacteria (Clifton et al., 1970). In light 
of our interest in CoA biosynthesis we decided to 
investigate this result further, and in 2002 published 
the first follow-up study of this work: we 
demonstrated that when the pantothenamide with 
a pentyl substituent (N5-Pan) is offered to the CoA 
biosynthetic enzymes, it is converted into the 
antimetabolite ethyldethia-CoA much faster than 
CoA is formed from pantothenic acid (Strauss & 
Begley, 2002). This suggested that N5-Pan acts as a 
bacterial growth inhibitor by reducing CoA levels, or 
because the antimetabolite product cannot act
                                                     
19 Currently, the term ‘antimicrobial’ is used as a general 
term for any compound that kill or arrest the growth of 
any microorganism, including bacteria, viruses, fungi and 
protozoa (usually parasites). The more commonly used 
‘antibiotic’ used to be synonymous with ‘antimicrobial’, 
but is now more widely used to refer to antibacterials, 
i.e. agents that are used in the treatment of bacterial 
infections.  
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Figure 7. Potential modes of action for N5-Pan, an antivitamin of pantothenic acid (vitamin B5): 1) Inhibition of PanK, and 
consequently CoA biosynthesis (leading to lowered CoA levels); 2) Conversion of N5-Pan into the antimetabolite 
ethyldethia-CoA by the CoA biosynthetic enzymes, causing inhibition of CoA-dependent enzymes (since the 
antimetabolite lacks the thiol group that is required for carrying acyl groups—see Figure 1); 3) Inhibition of fatty acid 
biosynthesis by inactivation of the acyl carrier proteins involved in this process by the antimetabolite. 
 
as an acyl carrier (see Section 2) because it lacks the 
requisite thiol, and therefore inhibits CoA-
dependent processes and/or fatty acid biosynthesis 
(Figure 7).  
Many research groups around the world picked 
up on this finding, and subsequently applied it in 
various contexts. Some tried to establish the mode 
of action of the pantothenamides, leading to the 
now generally held belief that they act through the 
inhibition of fatty acid biosynthesis (Zhang et al., 
2004). Others used the process as a way to label 
proteins (Mercer & Burkart, 2007). My own group 
was involved in work that showed that some 
pantothenamides are potent antiplasmodial agents 
(compounds that inhibit the growth of the malaria 
parasite, Plasmodium falciparum), although the 
compounds were unfortunately found to be prone 
to degradation (Spry et al., 2013). We also 
established a new method to prepare a small library 
(~150 compounds) of pantothenamides and their 
analogues in a simple and parallel fashion (van Wyk 
& Strauss, 2008) and most recently showed that the 
library members that have structural modifications 
compared to the parent compound are resistant to 
degradation (de Villiers et al., 2013). This has re-
opened the door to the development of these 
compounds as antimalarials, something we are 
currently actively pursuing. Finally, we are also 
revisiting the mode of antibacterial action of the 
pantothenamides, and have discovered that this is in 
fact very organism-specific, with the pathogen 
Staphylococcus aureus20 being most sensitive. Our 
findings in this regard may have far-reaching 
implications, both for the design of new 
antistaphylococcal agents and for the regulation of 
CoA biosynthesis in general. 
 
6.2 CJ-15,801: A surprisingly selective natural 
product 
In 2001 a Japanese research group working with 
the pharmaceutical company Pfizer discovered a 
curiously selective antibacterial agent in extracts 
from a Seimatosporium fungus (Sugie et al., 2001). 
This compound—which they named CJ-15,801—
only inhibited the growth of S. aureus, but none of 
the other bacteria that were tested. When the 
structure of the compound was elucidated, it was 
discovered that it was identical to vitamin B5 except 
for the addition of a double bond. This suggested 
that the compound’s inhibitory action was due to 
some effect on CoA biosynthesis, but it was unclear 
how this could be so selective. We took on the 
challenge to solve the mystery in collaboration with 
two groups from UC San Diego in the USA. 
                                                     
20 Staphylococcus aureus is known by several names and 
abbreviations: colloquially it is most often simply called 
‘Staph’, while in clinical settings it is also called ‘MRSA’ 
(pronounced ‘mirsa’), using the abbreviation for 
‘multidrug-resistant Staphylococcus aureus’. 
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Figure 8. Mode of action and selectivity of the natural 
product CJ-15,801. The inhibitor is activated only by 
PanK enzymes that can accept it as substrate (to date, 
only the PanK from S. aureus) and that therefore act as 
gatekeeper to its inhibition. Subsequently, PPCS catalyses 
the reaction of P-CJ with CTP to form P-CJ-CMP, which 
binds the enzyme tightly and prevents it from performing 
additional catalytic cycles (van der Westhuyzen et al., 
2012). 
 
By using a variety of biochemical analysis 
techniques we discovered that CJ-15,801 inhibits 
PPCS, the second enzyme of CoA biosynthesis, but 
only after it is activated by phosphorylation, i.e. once 
it can mimic the structure of the PanK reaction 
product. This activated form of CJ-15,801 
(phospho-CJ-15,801, or P-CJ) reacts with CTP in 
the active site of PPCS to form P-CJ-CMP, which 
acts as a structural analogue of the enzyme’s normal 
reaction intermediate. P-CJ-CMP remains tightly 
bound to the enzyme, and impairs its ability to 
perform catalysis—thereby blocking the formation 
of CoA. The consequent reduction in CoA levels is 
most likely the cause of cell growth arrest. 
However, this mechanism does not explain the 
compound’s selectivity. Since CJ-15,801 must be 
phosphorylated by PanK for it to act as a PPCS 
inhibitor, we tested the ability of various PanK 
enzymes to perform the reaction. We discovered 
that while none of the type I and type III PanKs 
tested could perform the reaction (see Section 4), 
the only known example of a bacterial type II 
PanK—the one from the targeted organism, S. 
aureus—was able to convert CJ-15,801 to P-CJ with 
an efficiency similar to that seen for pantothenic acid 
(its native substrate). This indicated that the PanK 
enzyme acted as a gatekeeper for CJ-15,801 
inhibition, and that only organisms with a PanK that 
would accept it as a substrate would experience 
inhibitory effects. This mechanism (summarised in 
Figure 8) is reminiscent of that of the 
sulphonamides, and revealed CJ-15,801 as a true 
antibacterial antimetabolite. This discovery of a new 
antivitamin, which also showed potential for use as 
an antibiotic, drew significant interest from the 
chemical biology community when it was published 
(van der Westhuyzen et al., 2012). It was highlighted 
in an accompanying ‘Preview’ article (Martinelli & 
Aldrich, 2012), and was also featured on the 
journal’s cover. We are still actively pursuing further 
studies based on these findings in our endeavour to 
find clinically useful inhibitors of CoA biosynthesis. 
 
 
7 FUTURE PROSPECTS 
 
Our knowledge and understanding of CoA 
biosynthesis have increased significantly over the 
past 15 years, and it has been both a pleasure and a 
privilege to have contributed to this process as 
highlighted in this article. However, much still 
remains to be done: in spite of our successes in the 
discovery of compounds that inhibit the growth of 
pathogenic bacteria and the malaria parasite, these 
still need to be developed further before it will be 
possible to apply them in a clinical setting. The focus 
of my group is shifting more and more to exploiting 
the differences in the human and pathogen CoA 
biosynthesis pathways for the discovery, design and 
development of new antimicrobial agents. This work 
requires the continued effort of MSc and PhD 
students with backgrounds in both chemistry and 
biochemistry, and I am therefore particularly pleased 
to be at the only university in South Africa which 
currently offers a BSc degree in Chemical Biology. 
The continued institutional support of this field and 
its development will be a crucial component of any 
future successes that we may achieve. 
In addition, my group’s research interests are 
also starting to expand beyond CoA biosynthesis. 
This shift was initiated by our interest in 
understanding how the bacterial pathogen S. 
aureus,21 which is rapidly becoming resistant to 
                                                     
21 In the United States, more people succumb to fatal 
antibiotic-resistant S. aureus infections than to 
HIV/AIDS-related illnesses. 
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every antibiotic we have in our clinical arsenal, 
survives the attacks that the human immune system 
launches on it to fight off infection.22 This interest 
was born from our curiosity about CoA, since S. 
aureus apparently uses the cofactor as part of its 
defence mechanisms against such attacks. This has 
opened new areas of study for us that have as their 
focus the importance and relevance of low 
molecular weight thiols (i.e. small molecules with  
–SH groups, such as CoA) in oxidative stress 
resistance, and in the enzymes that act on these 
thiols. We have already made some headway in this 
regard, with the design of the first inhibitors of the S. 
aureus CoADR enzyme that ensures that CoA 
remains reduced (van der Westhuyzen & Strauss, 
2010); in collaboration with research groups in the 
USA we have also managed to determine the 
structures of this protein in complex with our 
inhibitors (Wallace et al., 2012). This work is 
continuing as we now branch out our interest to 
enzymes that do not act on CoA, but which seem 
vital to S. aureus’s survival upon challenge with 
oxidative stress. 
The first 11 years of my independent career 
have been filled with excitement, frustrations, 
discoveries, challenges and immense pride in our 
achievements. I am thrilled to be able to build on 
these, and to be working with a team of 
postgraduate students that share my enthusiasm 
and optimism about what lies ahead as we continue 
to walk the paths along the CoA pathway, and 
beyond.  
 
 
                                                     
22 One of the first ways in which the human immune 
system respond to bacterial infections is to recruit 
certain types of white blood cells that try to engulf the 
bacteria (i.e. overtake them and then isolate them in a 
little vesicle, or bag, inside the white blood cell) where 
they are subsequently bombarded with oxidants (such 
as the equivalent of domestic bleach). This leads to the 
bacteria being killed in most cases, but some survive 
such kinds of oxidative stress, without any apparent 
affect. 
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